IP Library Granted Patent US 9,180,282
Granted Patent B2
US 9,180,282 · App. 12/555,257 · Granted Nov 10, 2015

Implantable drug delivery system having periodic drug delivery regimen to avoid granulomas

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,180,282
App. No.
12/555,257
Granted
Nov 10, 2015
Kind
B2
Abstract

An implantable drug delivery system including: a biocompatible or bio-inert housing containing a drug infusion pump, a drug chamber from which a liquid drug is dispensed when the pump applies a force to the drug chamber, and an internal controller actuating the pump; a delivery catheter extending from the housing to one or more drug delivery treatment sites in a target tissue, wherein the catheter includes a lumen having an inlet to receive a drug pumped from the drug chamber and an outlet are positioned at the target tissue, wherein the drug flows through the outlet to the target tissue, and wherein the internal controller stores and executes an automatic periodic flow regimen which commands the pump and drug chamber to periodically dispense an intermittent bolus or pulse of the liquid drug, wherein the periodic flow regimen provides a prophylactic treatment for granuloma.

Claims (21)

1. An implantable drug delivery system comprising:

a biocompatible or bio-inert housing containing a drug infusion pump, a drug chamber from which a liquid drug is dispensed when the pump applies a force to the drug chamber, and an internal controller actuating the pump;

a delivery catheter extending from the housing to one or more drug delivery treatment sites in a target tissue, wherein the catheter includes a lumen having an inlet to receive a drug pumped from the drug chamber and an outlet positioned at the target tissue, wherein the drug flows through the outlet to the target tissue, and

wherein the internal controller stores and executes an automatic periodic flow regimen which commands the pump and drug chamber to periodically dispense an intermittent bolus or pulse of the liquid drug, the periodic flow regimen including a drug delivery cycle having at least a first period of no drug infusion and a second period of drug delivery by the bolus or the pulse, wherein the first period is at least five times longer than the second period, wherein the periodic flow regimen provides a prophylactic treatment for granuloma, wherein the one or more drug delivery treatment sites is the spinal canal and the drug chamber contains a morphine based drug formulation, the implantable drug delivery system further comprising:

a memory; and

a processor coupled to the memory and configured with processor-executable commands to perform operations comprising:

receiving a drug dosage input value corresponding to a total quantity of the drug to be dispensed over a treatment period, wherein the treatment period is longer than the period of the drug delivery cycle; and

based on the received drug dosage input value, determining values corresponding to the first period of no drug infusion and the second period of drug delivery in the drug delivery cycle so as to provide the total quantity of the drug being dispensed over the treatment period as specified by the received drug dosage input value, wherein the value corresponding to the period of no drug infusion is determined based on a timing of a dissipation of the therapeutic effect resulting from the delivery by a bolus or pulse of the drug and a time period of no drug infusion needed to avoid granulomas proximate to the target tissue.

2. The implantable drug delivery system of claim 1 wherein the flow regimen includes a drug delivery cycle having at least a first period of no drug infusion and a second period of drug delivery by the bolus or the pulse, wherein the first period is at least five times longer than the second period and no more than twenty times longer than the second period.

3. A method for automatically dispensing a drug from an implantable drug delivery system having a biocompatible or bio-inert housing containing a drug infusion pump, a drug chamber, and an internal controller actuating the pump, and a delivery catheter, the method comprising:

receiving, at a controller, a drug dosage input value corresponding to a total quantity of the drug to be dispensed over a treatment period, wherein the treatment period is longer than a period of a drug delivery cycle;

based on the received drug dosage input value, determining values corresponding to a first period of no drug infusion and a second period of drug delivery in the drug delivery cycle so as to provide the total quantity of the drug being dispensed over the treatment period as specified by the received drug dosage input value, wherein the value corresponding to the period of no drug infusion is determined based on a timing of a dissipation of the therapeutic effect resulting from the delivery by a bolus or pulse of the drug and a time period of no drug infusion needed to avoid granulomas proximate to the target tissue;

programming a drug delivery regime for automatic drug infusion into the internal controller, wherein the drug delivery regime includes a periodic drug dispensing schedule comprising the drug delivery cycle having at least the first period of no drug infusion and the second period of drug delivery by a bolus or pulse of the liquid, wherein the first period is at least five times longer than the second period, to provide a prophylactic treatment to avoid granulomas proximate to a target tissue;

positioning the delivery catheter to one or more drug delivery treatment sites in a target tissue in a mammalian patient, wherein the one or more drug delivery treatment sites is the spinal canal and the drug chamber contains a morphine based drug formulation;

executing by the internal controller the drug delivery regime to periodically actuate the drug infusion pump to periodically discharge a bolus or pulse of a liquid containing the drug from the drug chamber and into the delivery catheter, and

periodically and automatically delivering the bolus or pulse of the liquid containing the drug to the target tissue.

4. The method of claim 3 wherein the drug delivery regime regimen includes a drug delivery cycle having at least a first period of no drug infusion and a second period of drug delivery by the bolus or the pulse of the liquid, wherein the first period is at least five times longer than the second period and no more than twenty times longer than the second period.

5. The implantable drug delivery system of claim 1 , wherein the first period of no drug infusion in the drug delivery cycle is greater than 3.5 hours.

6. The implantable drug delivery system of claim 1 , wherein the second period of drug delivery in the drug delivery cycle is between 1 minute and 24 minutes.

7. The method of claim 3 , wherein the first period of no drug infusion in the drug delivery cycle is greater than 3.5 hours.

8. The method of claim 3 , wherein the second period of drug delivery in the drug delivery cycle is between 1 minute and 24 minutes.

Assignments (14)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2025
From: FLO (ABC), LLC
To: ALGORITHM SCIENCES, INC.
Reel/Frame 070271/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2024
From: ALGORITHM SCIENCES, INC.
To: INFUSYN THERAPEUTICS, LLC
Reel/Frame 069258/0851 →
RELEASE OF SECURITY INTEREST Recorded Feb 17, 2023
From: SILICON VALLEY BANK
To: FLOWONIX MEDICAL INCORPORATED
Reel/Frame 062733/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2023
From: FLOWONIX MEDICAL INCORPORATED
To: FLO(ABC), LLC
Reel/Frame 062326/0374 →
SECURITY INTEREST Recorded May 6, 2022
From: FLOWONIX MEDICAL INCORPORATED
To: SWK FUNDING LLC
Reel/Frame 059840/0049 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 12, 2021
From: FLOWONIX MEDICAL INCORPORATED
To: SILICON VALLEY BANK
Reel/Frame 055297/0961 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 13, 2021
From: HERCULES CAPITAL, INC.
To: FLOWONIX MEDICAL INCORPORATED
Reel/Frame 054980/0672 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 30, 2020
From: PUMPERNICKEL HOLDINGS, LLC
To: FLOWONIX MEDICAL INCORPORATED
Reel/Frame 054895/0943 →
SECURITY INTEREST Recorded Sep 21, 2018
From: FLOWONIX MEDICAL INCORPORATED
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 046944/0066 →
SECURITY INTEREST Recorded May 22, 2017
From: FLOWONIX MEDICAL INCORPORATED
To: PUMPERNICKEL HOLDINGS LLC
Reel/Frame 042448/0122 →
CHANGE OF NAME Recorded Apr 10, 2012
From: MEDASYS INCORPORATED
To: FLOWONIX MEDICAL INCORPORATED
Reel/Frame 028023/0921 →
CHANGE OF NAME Recorded Jul 11, 2011
From: INSET TECHNOLOGIES INCORPORATED
To: MEDASYS INCORPORATED
Reel/Frame 026571/0801 →
CHANGE OF NAME Recorded Feb 8, 2011
From: INSET TECHNOLOGIES INCORPORATED
To: MEDASYS INCORPORATED
Reel/Frame 025772/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2010
From: ADLER, STEVEN C.; BURKE, PAUL
To: INSET TECHNOLOGIES INCORPORATED
Reel/Frame 024010/0869 →